
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
Immuneering is a promising company due to its innovative Disease Cancelling Technology platform, which has shown potential in treating RAS-driven tumors and preventing resistant disease. The upcoming MAPKeeper 301 trial will provide further validation for their drug atebimetinib, and the company's interactions with the FDA support their approach. While there are risks involved, long-term investors could see significant upside.
Bears say
Immuneering is facing several challenges with its drug development program, including potential competitiveness and low success rates in phase 3 trials. The company also relies heavily on patents and trade secrets for protection, which may pose risks if competitors develop similar treatments. This could lead to downward revisions in projections and price targets, while also requiring additional financing to support its drug development efforts.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares